About Us

News

November 30, 2021

SAN DIEGO , Nov. 30, 2021 /PRNewswire/ --  Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that Jude Onyia , Ph.D., has joined the company's executive management team as Chief Scientific Officer. Dr. Onyia , a scientist with more than 25 years of experience in the pharmaceutical

November 22, 2021

Neurocrine Biosciences anticipates initiating a Phase 2 study with the selective M4 agonist HTL-0016878 in schizophrenia in 2022 and Phase 1 studies for a dual M1/M4 and selective M1 agonist in 2023 Sosei Heptares receives US$100 million upfront, ongoing R&D funding, and up to US$2.6 billion in

November 9, 2021

SAN DIEGO , Nov. 9, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the following investor conferences:     Kevin Gorman , Chief Executive Officer, and Matt Abernethy , Chief Financial Officer will present at

November 1, 2021

INGREZZA® (valbenazine) Third Quarter 2021 Net Product Sales of $287 Million with Approximately 52,000 Total Prescriptions SAN DIEGO , Nov. 1, 2021 /PRNewswire/ --  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the third quarter ended September 30, 2021 .

November 1, 2021

SAN DIEGO , Nov. 1, 2021 /PRNewswire/ -- Neurocrine Biosciences , Inc. (Nasdaq: NBIX) today announced that it presented new data from its movement disorder program for tardive dyskinesia (TD) at the 2021 Psych Congress scientific meeting being held October 29–November 1, 2021.

October 16, 2021

SAN DIEGO , Oct. 16, 2021 /PRNewswire/ -- Neurocrine Biosciences , Inc. (Nasdaq: NBIX) today announced that it will present key information from its movement disorder treatments for Parkinson's disease and tardive dyskinesia (TD) at the American Neurological Association (ANA) 2021 Virtual Annual

October 11, 2021

Conference Call and Webcast Scheduled for Monday, November 1 SAN DIEGO , Oct. 11, 2021 /PRNewswire/ --  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report third quarter 2021 financial results after the Nasdaq market closes on Monday, November 1, 2021 .

Products

While others walk away from neuroscience because of risk and complexity, our team persists, resulting in four FDA-approved therapies.

Learn More
Leadership Team

Our mission to relieve patient suffering begins with our leadership team. They lead our effort to relentlessly pursue medicines to ease the burden of debilitating diseases and disorders.

Learn More